Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cassian Yee

Showing results (11-20 of 143) with videos related to

Pageof 15
Sort By:
Cancer Journal (Sudbury, Mass.)|April 15, 2017
Personalized Therapy: Tumor Antigen Discovery for Adoptive Cellular TherapyCassian Yee, Gregory A Lizee
The Journal of Clinical Investigation|April 15, 2024
Polyomavirus-positive Merkel cell carcinoma: the beginning of the beginningMichael K Wong, Cassian Yee
Cancer Discovery|May 16, 2012
Another LAP in the raceSylvia M Lee, Cassian Yee
Journal of Immunology (Baltimore, Md. : 1950)|August 6, 2005
IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell responseYongqing Li, Marie Bleakley, Cassian Yee
Journal for Immunotherapy of Cancer|April 24, 2023
Letter to the editor: Quality criteria for computational models predicting individual outcomes in CAR-T cell therapyAnna M Mc Laughlin, Cassian Yee
International Journal of Molecular Sciences|January 18, 2014
The effect of radiation on the immune response to cancersBonggoo Park, Cassian Yee, Kyung-Mi Lee
Cancer Journal (Sudbury, Mass.)|November 21, 2015
Endogenous T-Cell Therapy: Clinical ExperienceCassian Yee, Greg Lizee, Aaron J Schueneman
The Journal of Clinical Investigation|November 20, 2002
Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friendsWilliam Y Ho, Cassian Yee, Philip D Greenberg
Blood|October 5, 2021
Hematologic complications of immune checkpoint inhibitorsMichael H Kroll, Cristhiam Rojas-Hernandez, Cassian Yee
Nature|October 18, 2002
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activationVeronika Groh, Jennifer Wu, Cassian Yee, et al.
Pageof 15

Showing results (11-20 of 143) with videos related to

Sort By:
Pageof 15
Cancer Journal (Sudbury, Mass.)|April 15, 2017
Personalized Therapy: Tumor Antigen Discovery for Adoptive Cellular TherapyCassian Yee, Gregory A Lizee
The Journal of Clinical Investigation|April 15, 2024
Polyomavirus-positive Merkel cell carcinoma: the beginning of the beginningMichael K Wong, Cassian Yee
Cancer Discovery|May 16, 2012
Another LAP in the raceSylvia M Lee, Cassian Yee
Journal of Immunology (Baltimore, Md. : 1950)|August 6, 2005
IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell responseYongqing Li, Marie Bleakley, Cassian Yee
Journal for Immunotherapy of Cancer|April 24, 2023
Letter to the editor: Quality criteria for computational models predicting individual outcomes in CAR-T cell therapyAnna M Mc Laughlin, Cassian Yee
International Journal of Molecular Sciences|January 18, 2014
The effect of radiation on the immune response to cancersBonggoo Park, Cassian Yee, Kyung-Mi Lee
Cancer Journal (Sudbury, Mass.)|November 21, 2015
Endogenous T-Cell Therapy: Clinical ExperienceCassian Yee, Greg Lizee, Aaron J Schueneman
The Journal of Clinical Investigation|November 20, 2002
Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friendsWilliam Y Ho, Cassian Yee, Philip D Greenberg
Blood|October 5, 2021
Hematologic complications of immune checkpoint inhibitorsMichael H Kroll, Cristhiam Rojas-Hernandez, Cassian Yee
Nature|October 18, 2002
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activationVeronika Groh, Jennifer Wu, Cassian Yee, et al.
Pageof 15